SBD111

Bone loss is one of many health conditions exacerbated by inflammation. By harnessing the probiotic potential of fruit- and vegetable-derived microbes, Bondia™ targets the inflammatory signals that trigger bone degradation, while simultaneously strengthening the gut barrier to reduce further inflammation.

Findings

Through in vitro testing, Bondia™ was shown to increase gut barrier integrity, reduce inflammatory cytokine production from gut and immune cells, and reduce the activity of osteoclasts, specialized bone resorbing cells, in culture.

Findings

Through preclinical testing, increased concentrations of Bondia™ were shown to reduce bone loss, lessen inflammation, and reduce markers of bone turnover. Together, these results are indicative of Bondia™’s ability to reduce bone loss.

Findings

Bondia™ was recently evaluated for efficacy in a large randomized, double-blind, placebo-controlled clinical food trial in 286 early postmenopausal women. The study demonstrated Bondia™'s ability to slow bone loss in a prespecified population. The results are pending peer review and publication.

SBD121

Developed to be taken alongside the standard-of-care drug methotrexate, SBD121 is our Defined Microbial Assemblage (DMA™) that is currently undergoing clinical validation for the dietary management of rheumatoid arthritis as well as the gastrointestinal side effects of methotrexate.

Findings

Through in vitro tests, our candidate SBD121 was shown to increase gut barrier integrity, which can help the body better address the inflammation associated with rheumatoid arthritis. SBD121 was also shown to decrease inflammatory signals that can worsen rheumatoid arthritis symptoms.

Findings

In preclinical testing, SBD121 was found to reduce arthritis severity scores when consumed daily with methotrexate. Compared to methotrexate alone, usage of SBD121 in conjunction with methotrexate improved arthritis scores by approximately 50%.

Underway

SBD121 is currently being evaluated through a large randomized, double-blind, placebo-controlled clinical food trial enrolling early-stage rheumatoid arthritis subjects. Subjects are instructed to consume SBD121 twice-daily along with methotrexate. Through the clinical trial, SBD121 medical food will be evaluated for the dietary management of joint pain, swelling, inflammatory signals and gut barrier function.